Antibody molecules to dengue virus and uses thereof

Patent metadata

Field	Value
Publication number	US-10155806-B2
Application number	US-201615155620-A
Country	US
Kind code	B2
Filing date	May 16, 2016
Priority date	Feb 11, 2014
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.

First claim

We claim:

1. A nucleic acid molecule comprising a first nucleotide sequence encoding a heavy variable region of an antibody molecule capable of binding dengue virus, wherein the antibody molecule comprises:
(a) a heavy chain immunoglobulin variable region segment comprising:
a CDR1 comprising the sequence DVYMS (SEQ ID NO: 3),
a CDR2 comprising the sequence RIDPENGDTKYDPKLQG (SEQ ID NO: 4), and
a CDR3 comprising the sequence GWEGFAY (SEQ ID NO: 5); and

(b) a light chain immunoglobulin variable region segment comprising:
a CDR1 comprising the sequence RASENVDKYGNSFMH (SEQ ID NO: 6),
a CDR2 comprising the sequence RASELQW (SEQ ID NO: 7), and
a CDR3 comprising the sequence QRSNEVPWT (SEQ ID NO: 8).

2. An expression vector comprising the nucleic acid molecule of claim 1 .

3. An isolated host cell comprising the nucleic acid molecule of claim 1 .

4. The nucleic acid molecule of claim 1 , wherein the antibody molecule comprises a VH FW1 having the sequence QVQLVQSGAEVKKPGASVKVSCKAGFNIK (SEQ ID NO: 11).

5. The nucleic acid molecule of claim 1 , wherein the antibody molecule comprises a VH FW2 having the sequence WVRQAPGQGLEWMG (SEQ ID NO: 84) or WVRQAPEQGLEWMG (SEQ ID NO: 85).

6. The nucleic acid molecule of claim 1 , wherein the antibody molecule comprises a VH FW1 comprising a deletion of position 26 relative to SEQ ID NO: 33.

7. The nucleic acid molecule of claim 1 , wherein the antibody molecule comprises a VH amino acid sequence at least 85% identical to SEQ ID NO: 1.

8. The nucleic acid molecule of claim 1 , wherein the antibody molecule comprises the VH amino acid sequence of SEQ ID NO: 1.

9. The nucleic acid molecule of claim 1 , wherein the first nucleotide sequence encodes a VH amino acid sequence at least 85% identical to SEQ ID NO: 1.

10. The nucleic acid molecule of claim 1 , wherein the first nucleotide sequence encodes the VH amino acid sequence of SEQ ID NO: 1.

11. The nucleic acid molecule of claim 1 , which comprises a VH nucleotide sequence at least 85% identical to SEQ ID NO: 37.

12. The nucleic acid molecule of claim 1 , which comprises the VH nucleotide sequence of SEQ ID NO: 37.

13. The nucleic acid molecule of claim 1 , further comprising a second nucleotide sequence encoding a light chain variable region of the antibody molecule.

14. The nucleic acid molecule of claim 13 , wherein the antibody molecule comprises a VL amino acid sequence at least 85% identical to SEQ ID NO: 2.

15. The nucleic acid molecule of claim 13 , wherein the antibody molecule comprises the VL amino acid sequence of SEQ ID NO: 2.

16. The nucleic acid molecule of claim 13 , wherein the antibody molecule comprises the VH amino acid sequence of SEQ ID NO: 1 and the VL amino acid sequence of SEQ ID NO: 2.

17. The nucleic acid molecule of claim 13 , wherein the second nucleotide sequence encodes a VL amino acid sequence at least 85% identical to SEQ ID NO: 2.

18. The nucleic acid molecule of claim 13 , wherein the second nucleotide sequence encodes the VL amino acid sequence of SEQ ID NO: 2.

19. The nucleic acid molecule of claim 13 , which the first nucleotide sequence encodes the VH amino acid sequence of SEQ ID NO: 1 and the second nucleotide sequence encodes the VL amino acid sequence of SEQ ID NO: 2.

20. The nucleic acid molecule of claim 13 , which comprises a VL nucleotide sequence at least 85% identical to SEQ ID NO: 38.

21. The nucleic acid molecule of claim 13 , which comprises the VL nucleotide sequence of SEQ ID NO: 38.

22. The nucleic acid molecule of claim 13 , which comprises the VH nucleotide sequence of SEQ ID NO: 37 and the VL nucleotide sequence of SEQ ID NO: 38.

23. A nucleic acid molecule comprising a first nucleotide sequence encoding the VH amino acid sequence of SEQ ID NO: 1, a second nucleotide sequence encoding the VL amino acid sequence of SEQ ID NO: 2, or both.

24. A nucleic acid molecule comprising the VH nucleotide sequence of SEQ ID NO: 37, the VL nucleotide sequence of SEQ ID NO: 38, or both.

25. An expression vector comprising the nucleic acid molecule of claim 13 .

26. An expression vector comprising the nucleic acid molecule of claim 23 .

27. An expression vector comprising the nucleic acid molecule of claim 24 .

28. An isolated host cell comprising the nucleic acid molecule of claim 13 .

29. An isolated host cell comprising the nucleic acid molecule of claim 23 .

30. An isolated host cell comprising the nucleic acid molecule of claim 24 .

Assignees

• Visterra Inc

Inventors

• Robinson Luke
• Shriver Zachary
• Myette James R
• Babcock Gregory
• Viswanathan Karthik

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07K2317/90

  characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/567

  Framework region [FR] · CPC title